logo-loader
viewe-Therapeutics plc

New tool from e-Therapeutics will analyse genomics of type-2 diabetes patients to find new drugs

A new contract extends last December's agreement with Novo Nordisk for another six months to June 2020

diabetes
Novo Nordisk, which is the world’s largest producer of insulin, has the option to license relevant IP generated under the collaboration

Pharma giant Novo Nordisk has extended its contract with e-Therapeutics PLC (LON:ETX) for the UK drug discovery firm to help search for novel treatments for type-2 diabetes.

Extending the agreement for another six months to June 2020, e-Therapeutics will now also use its new Genome-Associated Interaction Networks (GAINs) technology to analyse patterns within the genomics data from patients with type-2 diabetes.

READ: e-Therapeutics eyes further partnerships and possibly M&A to fully exploit its potential

This extension, the first research agreement for the GAINs technology, follows on from the collaboration formed last December for e-Therapeutics’ Network-Driven Drug Discovery (NDD) platform to be used to try and find new intervention strategies, biological pathways and compounds to form new drugs.

Output from GAINs will also allow further work to be performed using the NDD technology, the Oxfordshire-based company said, and can also be included in any subsequent work and commercial agreement.

Novo Nordisk, which is the world’s largest producer of insulin, has the option to license relevant IP generated under the collaboration.

The pharma industry has had limited success from population genomics studies to understand the genetic basis of disease, said Ray Barlow, e-Therapeutics chief executive.

“Using GAINs, we are now able to interrogate genomics data from patients with complex, polygenic disease and shed new light on important and novel biological pathways for particular groups of patients.

“GAINs has potentially broad application in therapeutic, diagnostic and biomarker fields. We only began to market GAINs to the industry two months ago and are encouraged by the interest already shown.”

ETX chares were up 9% to 3.1p in early trading on Thursday.

Quick facts: e-Therapeutics plc

Price: 3.17 GBX

AIM:ETX
Market: AIM
Market Cap: £8.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

4 days, 21 hours ago

Holding(s) in Company

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 2 days ago

Holding(s) in Company

2 weeks, 2 days ago

Holding(s) in Company

2 weeks, 2 days ago

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read